Agilent Technologies vs Bio-Techne Corporation
Agilent holds the stronger position because it faces far less rival pressure and its instrument-software-service ecosystem blocks giant copycats, while Bio-Techne faces active reagent pricing pressure from rivals and is being acquired by Merck KGaA.
Agilent Technologies
Makes lab instruments (mass spec, chromatography) and diagnostics tools for research and clinical labs
Bio-Techne Corporation
Maker of antibodies, proteins, and reagent kits for life science research and diagnostics labs
Dimension by dimension
| Dimension | Agilent Technologies | Bio-Techne Corporation |
|---|---|---|
| Staying power of core product | Quarterly revenue held steady near $1.8 to $1.9 billion in recent quarters. | Q3 FY2026 organic revenue declined 2% amid softer biotech spending. |
| Exposure to AI absorbing the product | AI is unlikely to absorb its lab instruments and diagnostics tools. | AI is unlikely to absorb its reagents and instruments. |
| How easily a giant could copy them | Its combined instrument, software, and service ecosystem creates barriers that block a giant competitor from easily copying the business. | A giant competitor could feasibly replicate its reagent and instrument offerings. |
| Pressure from rivals | No meaningful customer loss visible in the evidence. | Faces undercutting from Sino Biological and ACROBiosystems on premium reagent pricing. |
| Financial footing | FY2025 revenue was $6.95 billion, with Q4 FY2025 at $1.86 billion and Q1 FY2026 at $1.80 billion, showing steadier scale. | FY2025 net sales were $1.2 billion with 5% organic growth and a 42.6% operating margin in Protein Sciences, though the most recent quarter turned negative organically. |
| Corporate control situation | No acquisition or ownership change is mentioned. | Being acquired by Merck KGaA at $73.00 per share, about $11.3 billion enterprise value, announced 2026-06-25. |
Questions people ask
- Is Bio-Techne being bought out?
- Yes. Merck KGaA agreed to acquire Bio-Techne at $73.00 per share, valuing the deal at about $11.3 billion enterprise value, announced on 2026-06-25. Agilent has no such deal in the given information.
- How do Agilent and Bio-Techne compare on revenue?
- Agilent's FY2025 revenue was $6.95 billion, several times larger than Bio-Techne's FY2025 net sales of $1.2 billion. Bio-Techne did post 5% organic growth for that year, but its most recent quarter showed a 2% organic decline.
- Does AI threaten Bio-Techne or Agilent's core products?
- Neither. Both companies are rated unlikely to have their core products absorbed by AI, since they make physical lab instruments, reagents, and diagnostic tools rather than software that AI could replace.
- Who is under more pricing pressure from competitors, Bio-Techne or Agilent?
- Bio-Techne is, facing direct undercutting from Sino Biological and ACROBiosystems on its premium reagent pricing. Agilent shows no comparable evidence of customer loss or pricing pressure in the given data.
Other comparisons with these companies